Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | 2026-07-16 15:37:51 | 11.96 | -1.08 | -8.28 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTLA | 0001652130 | Intellia Therapeutics, Inc. | US45826J1051 | 5493002T5BCPE5DZC723 | 364785571 | Nasdaq | 2835 | In Vitro & In Vivo Diagnostic Substances | 1231 | DE | 40 ERIE STREET | CAMBRIDGE | MA | 02139 | UNITED STATES | US | 857-285-6200 | 40 ERIE STREET, CAMBRIDGE, MA, 02139 | 40 ERIE STREET, CAMBRIDGE, MA, 02139 | — | Biotherapeutics | 2014 | John Leonard | 598 | http://intelliatx.com | 869,490,759 | 120,447,521 | 139,722,277 | Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. | 2026-07-16 17:04:56 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 869,490,759 | -1,047,463,553 | -54.6421 | 118,133,546 | 14,616,086 | 14.1194 |
| 2024 | 1,916,954,312 | -1,648,117,376 | -46.2296 | 103,517,460 | 7,411,055 | 7.7113 |
| 2023 | 3,565,071,688 | -324,002,575 | -8.3311 | 96,106,405 | 8,088,466 | 9.1896 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| James Basta, J.D. | General Counsel, Executive Vice President, Corporate Secretary | 2025 | 494,000 | 227,240 | 718,800 | — | 11,127 | 1,846,597 |
| David Lebwohl, M.D. | Chief Medical Officer, Executive Vice President | 2025 | 536,000 | 234,232 | 776,304 | — | 11,127 | 1,984,724 |
| John M. Leonard | Chief Executive Officer, President | 2025 | 708,000 | 529,230 | 2,443,920 | — | 26,429 | 5,063,899 |
| Edward J. Dulac | Treasurer, Executive Vice President, Chief Financial Officer | 2025 | 526,000 | 270,996 | 848,184 | — | 56,716 | 2,168,505 |
| Birgit Schultes, Ph.D. | Chief Scientific Officer, Executive Vice President | 2025 | 475,000 | 207,575 | 675,672 | — | 10,135 | 1,740,083 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 377 |
| 2024 | 403 |
| 2023 | 526 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 67,671,000 | 57,877,000 | 6,600,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | 67,671,000 | 57,877,000 | 36,275,000 |
| Research And Development Expenses | 388,861,000 | 466,311,000 | 435,069,000 |
| General And Administrative Expenses | 119,800,000 | 125,829,000 | 116,497,000 |
| Operating Expenses | 508,661,000 | 592,140,000 | 551,566,000 |
| Operating Income | -440,990,000 | -534,263,000 | -515,291,000 |
| Net Income | -412,694,000 | -519,021,000 | -481,192,000 |
| Earnings Per Share Basic | -3.81 | -5.25 | -5.42 |
| Earnings Per Share Diluted | -3.81 | -5.25 | -5.42 |
| Weighted Average Shares Outstanding Basic | 108,376,000 | 98,849,000 | 88,770,000 |
| Weighted Average Shares Outstanding Diluted | 108,376,000 | 98,849,000 | 88,770,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 12,104,000 | 13,605,000 | 13,605,000 |
| Marketable Securities Current | 294,420,000 | 412,333,000 | 685,475,000 |
| Accounts Receivable | 9,468,000 | 8,517,000 | 36,456,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | 1,000,000 |
| Other Assets Current | 68,359,000 | 29,831,000 | 49,651,000 |
| Total Assets Current | 527,711,000 | 639,863,000 | 998,330,000 |
| Marketable Securities Non Current | 155,250,000 | 260,215,000 | 99,864,000 |
| Property Plant And Equipment | 17,671,000 | 27,381,000 | 32,760,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 314,416,000 | 551,152,000 | 302,647,000 |
| Total Assets | 842,127,000 | 1,191,015,000 | 1,300,977,000 |
| Accounts Payable | 20,252,000 | 14,589,000 | 7,452,000 |
| Deferred Revenue | 7,290,000 | 20,661,000 | 22,140,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 49,862,000 | 55,355,000 | 67,017,000 |
| Total Liabilities Current | 103,884,000 | 110,851,000 | 115,208,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 66,849,000 | 208,208,000 | 135,600,000 |
| Total Liabilities | 170,733,000 | 319,059,000 | 250,808,000 |
| Common Stock | 12,000 | 10,000 | 9,000 |
| Retained Earnings | -2,590,094,000 | -2,177,400,000 | -1,658,379,000 |
| Accumulated Other Comprehensive Income | 1,032,000 | 605,000 | -2,258,000 |
| Total Shareholders Equity | 671,394,000 | 871,956,000 | 1,050,169,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 9,767,000 | 10,285,000 | 8,976,000 |
| Share Based Compensation Expense | 80,219,000 | 154,273,000 | 134,050,000 |
| Other Non Cash Income Expense | -527,000 | 76,000 | -72,000 |
| Change In Accounts Receivable | 951,000 | -27,939,000 | 32,688,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -2,811,000 | -917,000 | 707,000 |
| Change In Accounts Payable | 5,987,000 | 6,800,000 | 2,522,000 |
| Change In Other Liabilities | -5,271,000 | -10,383,000 | 6,024,000 |
| Cash From Operating Activities | -394,736,000 | -348,880,000 | -394,086,000 |
| Purchases Of Marketable Securities | 322,510,000 | 935,573,000 | 904,464,000 |
| Sales Of Marketable Securities | 551,670,000 | 1,066,918,000 | 887,102,000 |
| Acquisition Of Property Plant And Equipment | 1,129,000 | 5,778,000 | 13,985,000 |
| Acquisition Of Business | — | 287,000 | 287,000 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 228,031,000 | 125,567,000 | -31,347,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 128,175,000 | 2,986,000 | 3,929,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 131,486,000 | 185,747,000 | 130,323,000 |
| Change In Cash | -35,219,000 | -37,566,000 | -295,110,000 |
| Cash At End Of Period | 12,104,000 | 13,605,000 | 13,605,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -3.81 | -5.25 | -5.42 |
| Price To Earnings Ratio | -2.3596 | -2.221 | -5.6255 |
| Earnings Growth Rate | -27.4286 | -3.1365 | -12.013 |
| Price Earnings To Growth Ratio | 0.086 | 0.7081 | 0.4683 |
| Book Value Per Share | 6.195 | 8.8211 | 11.8302 |
| Price To Book Ratio | 1.4512 | 1.3218 | 2.5773 |
| Ebitda | -402,927,000 | -508,736,000 | -472,216,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 57,000 | 4,906,000 | 13,815,000 |
| Free Cash Flow | -394,793,000 | -353,786,000 | -407,901,000 |
| Return On Equity | -0.6147 | -0.5952 | -0.4582 |
| One Year Beta | 1.518 | 2.0896 | 1.9472 |
| Three Year Beta | 1.7399 | 2.083 | 2.1395 |
| Five Year Beta | 1.9674 | 1.7438 | 1.7647 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Dulac Edward J III | EVP, Chief Financial Officer | 2026-07-02 | 4,677 | D | 156,286 |
| Dube Michael P | VP, Chief Accounting Officer | 2026-07-01 | 2,641 | D | 66,886 |
| Bhanji Muna | Director | 2026-06-09 | 9,200 | A | 36,403 |
| Bhanji Muna | Director | 2026-06-09 | 13,300 | A | 13,300 |
| CHASE WILLIAM J | Director | 2026-06-09 | 9,200 | A | 143,893 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas R Carper | Senator | 2023-09-05 | Sale (Full) | 2023-08-25 | Spouse | $1,001 - $15,000 |
| Thomas R Carper | Senator | 2023-06-30 | Purchase | 2023-05-22 | Spouse | $1,001 - $15,000 |
| Thomas R Carper | Senator | 2020-12-02 | Purchase | 2020-11-20 | Spouse | $1,001 - $15,000 |
| James M Inhofe | Senator | 2018-11-08 | Sale (Full) | 2018-10-25 | Self | $15,001 - $50,000 |
| James M Inhofe | Senator | 2017-11-08 | Purchase | 2017-10-19 | Self | $15,001 - $50,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Donald Sternoff Honorable Beyer | 2021-08-07 | VA08 | Sale | 2021-07-21 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Cerro Pacific Wealth Advisors LLC | 2026-06-30 | 169,200 | 10,000 | 16.92 |
| INDEPENDENT FINANCIAL GROUP, LLC | 2026-06-30 | 254,684 | 15,052 | 16.9203 |
| Aventura Private Wealth, LLC | 2026-06-30 | 33,671 | 1,990 | 16.9201 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 2026-06-30 | 282,112 | 19,846 | 14.2151 |
| Spire Wealth Management | 2026-06-30 | 668,611 | 39,516 | 16.92 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| DFA INVESTMENT DIMENSIONS GROUP INC | 2026-04-30 | U.S. MICRO CAP PORTFOLIO - INSTITUTIONAL CLASS | DFSCX | 376,874 | 5,080,261.52 | 0.068 |
| Global X Funds | 2026-04-30 | Global X Russell 2000 ETF | RSSL | 48,088 | 648,226.24 | 0.0454 |
| EA Series Trust | 2026-04-30 | Burney U.S. Equity Select ETF | BRES | 500 | 6,740 | 0 |
| Dimensional ETF Trust | 2026-04-30 | Dimensional U.S. Equity Market ETF | DFUS | 37,911 | 511,040.28 | 0.0026 |
| Dimensional ETF Trust | 2026-04-30 | Dimensional U.S. Small Cap ETF | DFAS | 385,133 | 5,191,592.84 | 0.037 |